EN | RU
EN | RU

Help Support

Back

Comparison of esomeprazole and lansoprazole-based non-bismuth concomitant quadruple therapy to treat H. pylori

Comparison of esomeprazole and lansoprazole-based non-bismuth concomitant quadruple therapy to treat H. pylori Comparison of esomeprazole and lansoprazole-based non-bismuth concomitant quadruple therapy to treat H. pylori
Comparison of esomeprazole and lansoprazole-based non-bismuth concomitant quadruple therapy to treat H. pylori Comparison of esomeprazole and lansoprazole-based non-bismuth concomitant quadruple therapy to treat H. pylori

This retrospective analysis compared the rates of eradication of non-bismuth concomitant quadruple therapy comprising of either esomeprazole and lansoprazole for first-line anti-H. pylori treatment.

See All

Key take away

A seven-day concomitant treatment (non-bismuth concomitant quadruple therapy) with either esomeprazole or lansoprazole showed comparable rates of eradication in H.pylori infected patients. Also, the eradications were possibly affected by metronidazole-resistant strains.

Background

This retrospective analysis compared the rates of eradication of non-bismuth concomitant quadruple therapy comprising of either esomeprazole and lansoprazole for first-line anti-H. pylori treatment.

Method

In total, 206 H. pylori-infected patients were enrolled and assigned into two groups based on esomeprazole and lansoprazole based concomitant therapies as:

  • EACM group: Esomeprazole 40 mg + Amoxicillin 1 g + Metronidazole 500 mg; and Clarithromycin 500 mg all taken twice daily for 7 days
  • LACM group: Lansoprazole 30 mg + Amoxicillin 1 g + Metronidazole 500 mg; and Clarithromycin 500 mg  all taken twice daily

After 8 weeks, patients were asked to carry out urea breath tests.

Result

Rates of eradication in the EACM group and LACM group in intention-to-treat (ITT) and the per-protocol (PP) analysis is depicted in the following table:


Patients in the LACM group displayed more diarrhea compared to the EACM group (7.1% vs. 1.0%), however, all were mild symptoms. Metronidazole resistance was the clinical feature influencing the eradications as per the univariate analysis. Furthermore, a trend was witnessed in dual metronidazole- and clarithromycin-resistant strains. 

Conclusion

Non-bismuth concomitant quadruple therapy with either esomeprazole or lansoprazole provided similar outcomes concerning eradication rates for first-line therapy for H. pylori. In the PP analysis, both groups could attain more than 90% elimination of H. pylori.

Source:

Infection and Disease resistance

Article:

Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice

Authors:

Kuo-Tung Hung al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: